PL BioScience Launches World's Only Patented Gamma-irradiated Human Platelet Lysate
AACHEN, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the launch of ELAREM™ Ultimate-FD PLUS, the only gamma-irradiated, GMP-grade Human Platelet Lysate produced in Germany using a globally patented process. With the increasing demand for safe, xeno-free, ethically sourced cell culture supplements in cell therapy, regenerative medicine, and biopharmaceutical manufacturing, ELAREM™ Ultimate-FD PLUS answers a critical industry need: a virus-inactivated, animal-free, and EU-manufactured alternative that meets the highest quality standards.
'We are thrilled to bring the only gamma-irradiated Human Platelet Lysate produced in Europe to the dynamic field of cell and gene therapy,' said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. 'This product isn't just a milestone for Europe – it's a globally unique offering. With comprehensive patent protection and fully EU-based production, ELAREM™ Ultimate-FD PLUS ensures a stable supply chain and offers global manufacturers a high-quality, regulatory-ready solution that meets the highest international standards.'
Cell culture supplements are essential for growing cells in the laboratory. They play a critical role in the development and manufacturing of advanced therapies like cell and gene therapies. Traditionally, these supplements often contain components derived from other species, such as fetal bovine serum (FBS). These animal-derived products carry potential safety risks, for example bacterial or viral contamination, and pose ethical concerns. HPL offers a fully human-derived, xeno-free alternative that is safe, consistent, and sustainable.
ELAREM™ Ultimate-FD PLUS takes this one step further. Through a proprietary gamma-irradiation process, the product undergoes viral inactivation to add an extra layer of safety and regulatory assurance. The gamma-irradiated, xeno-free, fibrinogen-depleted, and anticoagulant-free product complies with the relevant GMP (Good Manufacturing Practice) guidelines. This makes it especially suitable for cell manufacturing applications where viral reduction is critical, such as potential use in clinical trials.
About Human Platelet Lysate:
Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.
In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.
ELAREM™, PL BioScience's line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/
Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
[email protected]
Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
23 minutes ago
- Business Upturn
MUSE Microscopy, Inc. Launches Veterinary Digital Pathology with the First-of-Its-Kind Tissue-to-Direct Digital Imaging for the Veterinary Market
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — MUSE Microscopy, Inc., a pioneer in digital pathology innovation, today announced the formation of MUSE Veterinary Digital Pathology, LLC, a wholly-owned subsidiary focused on transforming pathology through point-of-care service. This initiative aims to provide same-day results for tissue biopsies. This new service will provide the gold standard of patient care allowing veterinarians to deliver pet parents with diagnosis, prognosis, and treatment plans efficiently using the SmartPath MUSE Technology™ (SmartPath)* Platform. The strategic move signifies MUSE's formal entry into the veterinary health market, bringing point-of-care and real-time diagnostic imaging to specialty, emergency, and family veterinary practices nationwide. Utilizing the unique capabilities of SmartPath for rapid, non-destructive tissue imaging, MUSE Veterinary Digital Pathology empowers veterinarians to make real-time treatment decisions, marking a significant innovation in tissue pathology in the past century. Matthew Nunez, CEO of MUSE Microscopy, will lead MUSE Veterinary Digital Pathology supported by a seasoned executive, Darin Nelson, who has a proven track record in building and scaling veterinary diagnostic companies. He acquired more than 800 animal hospitals for both VCA and Thrive Pet Healthcare and helped pet insurer Trupanion go public. Darin will join the company as President. Dr. Jeffrey Edwards, DVM, MPH, MRVCS, DAVCP, a clinical leader in veterinary diagnostics in his storied career, has been appointed as Chief Medical Officer overseeing the anatomic pathology team and the translational adoption of our innovative technology in veterinary practices nationwide.. Advertisement 'This launch represents a natural and strategic expansion of our technology platform,' stated Matthew Nunez. 'The veterinary sector is primed for innovation in diagnostic speed and precision. With MUSE Veterinary Digital Pathology, we are delivering state-of-the-art digital pathology directly to the point-of-care, empowering veterinarians to deliver faster diagnoses, reduce unnecessary delays, and elevate patient care.' MUSE Veterinary Digital Pathology will initially target specialty and emergency practices and large general practices, expected to commence in Q4 2025. The platform's intraoperative capabilities, same day results, and SmartPath's tissue-to-digital imaging will provide real-time surgical margin assessments and tissue diagnostics without reliance on current conventional slide-based workflows. 'This is about putting powerful diagnostic tools directly into the hands of veterinarians when and where they need them most,' stated Darin Nelson. 'Our goal is to enable faster decision-making, minimize wait times, and ultimately improve clinical outcomes for animal patients.' 'Veterinary medicine is long overdue for this level of innovation,' added Dr. Jeffrey Edwards. 'With our groundbreaking technology, we can reduce the delay in receiving biopsy results currently requiring couriers and 3-7 days down to same day diagnosis, changing the entire dynamic of medical management and clinical decision making as well as alleviated owner anxiety of waiting.' MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy's existing infrastructure, regulatory framework, personnel, and proprietary imaging technologies. The company anticipates additional announcements in the coming months, including pilot partnerships and distribution opportunities across the U.S. and internationally. About MUSE Microscopy, Inc. MUSE Microscopy is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath)*, is a slide-free direct-to-digital imaging platform that aims to transform the patient's experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at or find them on social media platforms such as Twitter, Facebook, and LinkedIn. *Pending FDA approval. Limits on Accuracy This press release is intended to provide information about MUSE Microscopy, Inc.'s research and potential product. Information is believed to be accurate at the time it is created. However, like any printed material, information may become outdated over time. Information may contain technical inaccuracies or typographical errors. Information may be changed or updated without notice. There may also be improvements or changes in the products and services described in this press release at any time without notice. It is important that you rely on the advice of an appropriate professional. Nothing contained in any presentation is to be construed as medical, legal, investment, financial, or other advice. This information is not intended to be a substitute for such advice. MUSE Microscopy, Inc., does not endorse any specific techniques or methods of treatment. Individuals are advised to consult their health care professionals for full information about the potential adverse reactions from use of the medical technologies discussed in this press release. We will use reasonable efforts to include accurate and up-to-date information on the website, but MUSE Microscopy, Inc. makes no warranties or representations as to its accuracy. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans, prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. MEDIA CONTACT: Matthew Nuñez Tel: 949.813.6121 [email protected] Source: MUSE Microscopy, Inc. Join the Evolution. Embrace the Future. #DigitalPathology #SlideFreeRevolution #SmartPathMUSE For more information about MUSE Microscopy and its innovative technologies, please visit Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
23 minutes ago
- Business Upturn
Amdark Limited Offers Investment Fraud Recovery Program to Combat Surge in Online Scams in 2025
By GlobeNewswire Published on June 10, 2025, 00:21 IST Amdark Limited , a top-tier financial recovery services provider, has unveiled a fraud recovery program, emphasizing the importance of tracking and recovering funds in online scams in 2025. CHELMSFORD, United Kingdom, June 09, 2025 (GLOBE NEWSWIRE) — In the latest news, Amdark Limited offers an investment fraud recovery program that helps to track and recover online scams. Investment fraud happens when someone lies or misleads others into investing money, often with false promises of guaranteed profits, low risk, or quick returns. The scammer might pose as a financial advisor, broker, or company representative and may use fake websites, social media ads, or phone calls to gain your trust. Significance of Investment Fraud Recovery Services Online scams have become a significant concern in the digital finance space, affecting both novice and experienced investors. Fraudulent schemes, such as Ponzi schemes, phishing attacks, fake Initial Coin Offerings (ICOs), and rug pulls, are just a few of the ways scammers target their victims. The decentralized and anonymous nature of crypto transactions makes it incredibly difficult to trace and reverse these fraudulent activities. Many traditional banking systems offer ways to dispute transactions, the irreversible nature of crypto transactions means that stolen funds are typically lost forever. This leaves victims in a position where they may feel helpless, as recovering lost assets requires specialized knowledge and resources. In such cases, Amdark Limited steps in to help victims navigate the complex and often opaque world of crypto scam recovery. Reasons Behind Investment Fraud Growing in 2025 Technology makes it easier than ever to connect with people but it also gives scammers new tools to exploit victims. However, individuals are investing and building a secure future but simultaneously face cybercrime issues. Amdark Limited helps track every scam and offers crypto forensic services for regulators, law enforcement, companies, and individuals to ensure that the individual's transactions are safe and secure. When individuals need a high level of accuracy for witness or rediscovery, the company assists the clients in evaluating their legal situations and provides accurate and up-to-date forensic data. It also offers the latest technology and data recovery services, which help identify and extract data from computers and other advanced devices. Amdark Limited Investment Recovery Program Protects Investment Fraud The company shed light on how to avoid falling victim: Do Your Research – Always investigate the company, the people involved, and the investment itself. Google reviews, search for scam warnings and check financial regulatory websites. – Always investigate the company, the people involved, and the investment itself. Google reviews, search for scam warnings and check financial regulatory websites. Verify Licensing – Legitimate brokers or advisors must be registered. Use government or financial watchdog websites to confirm credentials. – Legitimate brokers or advisors must be registered. Use government or financial watchdog websites to confirm credentials. Avoid 'Risk-Free' Offers – No investment is risk-free. Be wary of anyone claiming otherwise. – No investment is risk-free. Be wary of anyone claiming otherwise. Don't Trust Social Media Alone – Just because an ad appears on Facebook or Instagram doesn't mean it's trustworthy. Always double-check before handing over your money. – Just because an ad appears on Facebook or Instagram doesn't mean it's trustworthy. Always double-check before handing over your money. Consult an Expert – Before investing large amounts, speak to a licensed financial advisor or a legal expert in finance. Fund Recovery Services Matter Scammers are clever, and once they've taken their money, they rarely leave a trail. That's where professionals come in. Fund recovery agencies combine legal, forensic, and digital tools to track their stolen funds and attempt to retrieve them. While not all cases lead to full recovery, many victims have successfully reclaimed a portion or even all of their lost investments through expert help. Furthermore, investment fraud is one of the fastest-growing financial crimes in 2025, and its consequences are both emotional and financial. To combat this online scam chain, Amdark Limited brings real solutions and become a trusted partner in investment fraud recovery that can guide them through the process of reclaiming what's there. About Amdark Limited: For over 20 years, Amdark Limited has been an emerging provider of financial recovery services, specializing in helping victims of online scams recover their losses. The company has a team of experienced financial experts who have a proven track record of success. Amdark Limited offers a free consultation to assess each case and determine the possibility of recovery. Media Contact:Company Name: Amdark LimitedContact person:Alan Kalbfell Contact email: [email protected] Website link: Disclaimer: This press release is provide d by the Amdark Limited. Th e statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing involves significant risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
23 minutes ago
- Business Upturn
XRP News: XpFinance Presale Surges Past 30 Percent, With Only 8 Days Left Before Exchange Listings
VILNIUS, Lithuania, June 09, 2025 (GLOBE NEWSWIRE) — Investor excitement is reaching new heights as XpFinance , the revolutionary decentralized lending and borrowing platform built exclusively for XRP and XRPL native assets, announces that its XPF token presale has surpassed 30 percent of its allocation with just eight days remaining. With XRP trading strongly above two dollars and forty cents, market conditions couldn't be better timed for XpFinance 's final presale phase. Early investors have rushed to secure tokens, locking in a presale price of 1 XRP per 200 XPF. Join XpFinance Presale This phase marks investors' last opportunity to purchase XPF tokens at presale rates, creating intense urgency to participate before tokens list on prominent decentralized exchanges like XPMarket. Upon presale conclusion, XPF tokens will immediately be listed at a rate 30 percent higher than the presale price, granting early participants an instant advantage and substantial potential upside from day one. This built-in 30 percent gain, combined with the robust functionality and clear utility of the platform, explains why over 300 investors have swiftly joined the presale, rapidly pushing XpFinance into the spotlight as one of 2025's top DeFi projects on the XRP Ledger. Why XpFinance Is Gaining Massive Attention Unlike short-term crypto plays, XpFinance offers a genuinely decentralized, fully transparent financial infrastructure without intermediaries or centralized authorities. The platform empowers XRP holders to effortlessly lend, borrow, and earn passive income securely on-chain, finally unlocking the true DeFi potential of the XRP Ledger. Crypto influencers and XRP analysts are already buzzing about XpFinance, highlighting its groundbreaking approach to decentralized finance. By seamlessly merging XRP Ledger's unrivaled speed and security with decentralized governance, XpFinance sets itself apart, providing investors with a compelling entry point into XRPL's rapidly evolving DeFi landscape. Buy XPF Tokens Key Benefits for XPF Token Holders XpFinance is built upon three critical pillars: security, transparency, and community governance. Investors holding XPF tokens immediately unlock tangible benefits, including: Passive Income: Holders staking XPF tokens earn continuous XRP rewards generated directly from platform transaction fees, creating reliable and predictable yield. Reduced Borrowing Costs: Simply holding XPF significantly reduces interest rates on loans, maximizing financial efficiency and enabling greater participation in the lending ecosystem. Governance Rights: XPF token holders have direct voting power to shape the future of XpFinance. This includes deciding on new asset listings, risk parameters, platform enhancements, and feature implementations, ensuring continuous alignment with community needs. How to Secure Your XPF Tokens Before the Presale Ends With just eight days remaining and presale allocations quickly filling, prospective investors need to act fast to capitalize on the guaranteed 30 percent upside upon token listing. Here's how to secure your XPF allocation: Acquire XRP: Purchase XRP tokens from leading exchanges like Binance, Coinbase, or Bybit. Transfer to Self-Custody Wallet: Move your XRP tokens to a secure non-custodial wallet that supports the XRP Ledger, such as Xaman, XUMM, or Ledger. Participate in the Presale: Visit the official presale portal at , copy the presale deposit address, and send your desired XRP contribution. Set Up Your XPF Trustline: Add the XPF trustline to your wallet , ensuring you automatically receive tokens when the presale concludes. Join the Xpfinance telegram community to stay updated on the latest news. XpFinance represents more than just a promising presale. It marks a transformative step forward in decentralized finance on the XRP Ledger. With imminent exchange listings and the highly anticipated platform demo launch next week, early adopters are uniquely positioned to reap substantial benefits. Join hundreds of XRP investors already securing their XPF tokens and claim your stake in the future of decentralized finance. Visit Website: Join Presale: Telegram Community: Follow On X: Contact: [email protected] Contact:Alex Carter [email protected]
